Portrait No. 001
Crystal Nyitray
CEO & Founder
Encellin
Raised — 13M
My spark came from something I couldn't unsee: the invisible, relentless burden carried by people managing Type 1 diabetes every single day. Counting carbs, calibrating doses, waking at 3am to check glucose. Current treatments extend life, but they don't restore it. As a PhD student, I became convinced that the body's own cells held the answer. Not a better drug, but a living solution that works the way the body was designed to. When I brought this idea to my mentor, she challenged me: \"People have been thinking about this for a long time. What are you doing differently?\" That question didn't discourage me. It clarified everything. Why me, why now? I sit at the intersection of the science, the clinical reality, and the entrepreneurial urgency this problem demands. Patients have already waited long enough, and if I have the ability to change that, it felt like my responsibility to try.
In her words
“I am a first-generation American, the daughter of a Nicaraguan mother and a Czechoslovak father, and I never quite fit neatly into any one world.”
Chapter I
The toughest challenges you've faced as a founder.
Building Encellin has never been the path of least resistance. I am a first-generation American, the daughter of a Nicaraguan mother and a Czechoslovak father, and I never quite fit neatly into any one world. I learned early that being a little out of place is actually a superpower. That comfort with being different is exactly what gives us the audacity to believe we can fundamentally change medicine. My plan was always audacious, maybe even naive to some, because we were asking the world to rethink what medicine could be. But there was always a plan. I earned full rides through both undergrad and graduate school on fellowships, built the science, and then proved it could win in the arena. MedTech Innovator. The ADA Showcase. JLabs QuickFire Challenge. Y Combinator. A financing round led by Khosla Ventures. And now, a completed first-in-human clinical trial with best-in-class data. Nobody handed us a playbook. We wrote it. Growing up between worlds taught me that conventional thinking protects the status quo, and the status quo is failing patients. That's not a burden. That's a mandate.
Chapter II
Your vision.
I am obsessed with a simple but radical idea: that the human body already knows how to heal itself, and our job is to get out of its way. Right now, millions of people with Type 1 diabetes, hypoparathyroidism, and other chronic diseases are managed, not cured. They are tethered to drugs, devices, and daily interventions for life. We accept this as normal. I don't. Encellin is building a future where a single implant, loaded with living cells, restores the body's ability to regulate itself. No daily injections. No lifelong immunosuppression. Just biology, doing what biology does best. If we get this right, we don't just change diabetes. We unlock a new category of medicine, where living cells become the therapy, and chronic disease is no longer a life sentence. That is the world I am building toward. And we have the data to believe it's possible.
Chapter III
The impact you want to leave behind — for your industry, your community, and the women who come next.
Thirty years from now, I want the next generation of scientists, especially young women, daughters of immigrants, kids who never quite fit in, to look at what Encellin built and see themselves in it. I want to have proven that you don't have to follow the conventional path to change medicine. That being different is not a liability, it's the whole point. And I want chronic disease to mean something different than it does today. Not a life sentence managed with pills and devices, but a condition medicine actually solved. That's the legacy. Better medicine. And a clearer path for everyone who comes next.